Zhejiang Wolwo Bio-Pharmaceutical Co Ltd

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 12.18, indicating a high ability to meet short-term obligations. The company's liquidity_fpt score is high, supported by a net cash position that is negative after subtracting total debt, but the overall debt burden is minimal, with a debt-to-equity ratio of 0.01. This low leverage suggests a conservative capital structure, which is typical for firms in the pharmaceutical industry. In terms of profitability, the company's return on equity (ROE) of 14.54% and return on assets (ROA) of 13.15% are both well above the industry median, indicating strong returns relative to its peers. The gross profit margin of 95.25% (calculated as gross profit / revenue) is also robust, suggesting efficient cost management and pricing power in its product lines. The company's revenue is concentrated in a single geographic market, China, which accounts for 100% of its disclosed revenue. While this concentration may offer scale advantages, it also exposes the company to regulatory and macroeconomic risks specific to the Chinese market. No material segment disclosures are available, but the company's product portfolio is likely diversified across therapeutic areas, as is common in the pharmaceutical industry. Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the next fiscal year. The capital expenditure of -119.35 million CNY suggests a reduction in investment, which may reflect a shift toward cost optimization or a mature product lifecycle. The company's free cash flow of 189.19 million CNY provides flexibility for dividends, debt reduction, or strategic investments. The company's risk profile is moderate, with a liquidity risk score of medium and a dilution risk score of low. The low dilution risk is supported by a stable share count, with no difference between basic and diluted shares outstanding. However, the negative net cash position after subtracting total debt is a flag to monitor, as it could signal pressure on liquidity if operating cash flow declines. Recent filings and transcripts do not indicate any material events or strategic shifts. Analysts have assigned a mean recommendation of 2.00 (Buy), with three Buy ratings and no Strong Buy or Hold ratings. The mean price target of 30.92 CNY suggests a moderate upside from current levels.